Cover Image
市場調查報告書

胸腺癌:開發中產品分析

Thymus Cancer - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 213054
出版日期 內容資訊 英文 109 Pages
訂單完成後即時交付
價格
Back to Top
胸腺癌:開發中產品分析 Thymus Cancer - Pipeline Review, H1 2016
出版日期: 2016年04月30日 內容資訊: 英文 109 Pages
簡介

胸腺癌是胸腺發生的罕見癌症。症狀有呼吸急促,咳嗽,胸部疼痛,吞嚥困難,食慾不振,頭痛,體重減少等。因素有年齡及其他自體免疫疾病(重症肌無力,純紅血球再生不良症,低丙種球蛋白血症等)。

本報告提供胸腺癌的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

胸腺癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Merck & Co., Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • Onxeo SA
  • 大日本住友製藥

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • amrubicin hydrochloride
  • belinostat
  • buparlisib hydrochloride
  • Cell Therapy 1 for Oncology
  • milciclib
  • MK-2206 + selumetinib sulfate

開發中產品的最新趨勢

產品開發的里程碑

  • 熱門新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8063IDB

Summary

Global Markets Direct's, 'Thymus Cancer - Pipeline Review, H1 2016', provides an overview of the Thymus Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thymus Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thymus Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thymus Cancer
  • The report reviews pipeline therapeutics for Thymus Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Thymus Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Thymus Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Thymus Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Thymus Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thymus Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Thymus Cancer - Overview
  • Thymus Cancer - Therapeutics under Development by Companies
  • Thymus Cancer - Pipeline Products Glance
    • Clinical Stage Products
  • Thymus Cancer - Products under Development by Companies
  • Thymus Cancer - Companies Involved in Therapeutics Development
    • Cellceutix Corporation
    • Merck & Co., Inc.
    • Novartis AG
    • Onxeo SA
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Taiwan Liposome Company, Ltd.
    • Tiziana Life Sciences Plc
  • Thymus Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • amrubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • belinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KM-3174 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • milciclib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-2206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-2206 + selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TLC-388 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Thymus Cancer - Recent Pipeline Updates
  • Thymus Cancer - Dormant Projects
  • Thymus Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Aug 11, 2015: Cellceutixs Kevetrin and Thymoma - a Rare Cancer
      • Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014
      • May 14, 2014: Phase II data of Nerviano Medical Science's kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO
      • Jul 18, 2013: Belinostat gets European orphan drug designation for the treatment of malignant thymomas
      • May 17, 2012: Topotarget Presents Phase I/II Clinical Data Of Belinostat At ASCO 2012
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thymus Cancer, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Thymus Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Thymus Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Thymus Cancer - Pipeline by Novartis AG, H1 2016
  • Thymus Cancer - Pipeline by Onxeo SA, H1 2016
  • Thymus Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Thymus Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
  • Thymus Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Thymus Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Thymus Cancer - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Thymus Cancer, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top